Elena Bravver
About
Elena Bravver is a scholar working on Neurology, Genetics and Molecular Biology.
According to data from OpenAlex, Elena Bravver has authored 18 papers receiving a total of 163 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Neurology, 7 papers in Genetics and 5 papers in Molecular Biology. Recurrent topics in Elena Bravver's work include Amyotrophic Lateral Sclerosis Research (12 papers), Neurogenetic and Muscular Disorders Research (7 papers) and Muscle Physiology and Disorders (4 papers). Elena Bravver is often cited by papers focused on Amyotrophic Lateral Sclerosis Research (12 papers), Neurogenetic and Muscular Disorders Research (7 papers) and Muscle Physiology and Disorders (4 papers). Elena Bravver collaborates with scholars based in United States, United Kingdom and Japan. Elena Bravver's co-authors include Benjamin Rix Brooks, Mohammed Sanjak, William L. Bockenek, H. James Norton, Nicole Williams, Sara Hammond, Mark A. Hirsch, Nigel Rozario, Charity G. Patterson and Heather J. Sutherland and has published in prestigious journals such as Neurology, Archives of Physical Medicine and Rehabilitation and Muscle & Nerve.
In The Last Decade
Elena Bravver
16 papers receiving 152 citations
Peers
Elena Bravver
Dagmar Kettemann Germany
Nicola Cooke United Kingdom
Acary Bulle Oliveira Brazil
Paolo Volanti Italy
Theresa Walsh United Kingdom
Bertram Walter Germany
Elza Dias‐Tosta Brazil
Jonathan Marra United States
Stephen Wørlich Pedersen Denmark
Valentina Solara Italy
Citations per year, relative to Elena Bravver Elena Bravver (= 1×)
peers
Dagmar Kettemann
Countries citing papers authored by Elena Bravver
Since
Specialization
Citations
This map shows the geographic impact of Elena Bravver's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elena Bravver with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elena Bravver more than expected).
Fields of papers citing papers by Elena Bravver
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Elena Bravver. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elena Bravver. The network helps show where Elena Bravver may publish in the future.
Co-authorship network of co-authors of Elena Bravver
This figure shows the co-authorship network connecting the top 25 collaborators of Elena Bravver. A scholar is included among the top collaborators of Elena Bravver based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elena Bravver. Elena Bravver is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Reash, Natalie F., M. James, Lindsay N. Alfano, et al.. (2022). Comparison of strength testing modalities in dysferlinopathy. Muscle & Nerve. 66(2). 159–166.
2.
Brooks, Benjamin Rix, et al.. (2020). Early Treatment Effects of Riluzole in ALS: Isometric Strength Improvement in Sentinel Muscles Correlates with Improved Survival (4121). Neurology. 94(15_supplement).
3.
Wright, Kathryn, et al.. (2019). Dextromethorphan-Quinidine (Nuedexta) Improves Swallowing in Bulbar Onset ALS Patients with Pseudobulbar Affect - Pre-Post Observational Study in 86 ALS Patients (P4.4-019). Neurology. 92(15_supplement).
4.
Jacobs, Marni, M. James, Anna Mayhew, et al.. (2019). P.183Functional progression in dysferlinopathy: results of a 3-year natural history study. Neuromuscular Disorders. 29. S102–S102.
5.
Statland, Jeffrey, Anthony A. Amato, Elena Bravver, et al.. (2018). Preliminary Results from a Phase 2 Study to Evaluate ACE-083, a Local Muscle Therapeutic, in Patients with Facioscapulohumeral Muscular Dystrophy (S38.001). Neurology. 90(15_supplement).
6.
Statland, Jeffrey, Elena Bravver, Chafic Karam, et al.. (2018). FSHD / OPMD / EDMD / DMI. Neuromuscular Disorders. 28. S140–S140.
7.
Sanjak, Mohammed, Elena Bravver, William L. Bockenek, et al.. (2018). C-Reactive Protein ( CRP ) is Significantly Higher in Amyotrophic Lateral Sclerosis (ALS) Patients on Non-Invasive Ventilation (NIV) and Tracheostomy-Invasive Ventilation (TIV) Compared with ALS Patients at Intake Clinic Evaluation and Decreases Following Riluzole Administration – Is CRP Potentially a Biomarker for Treatment Responsiveness? (P4.447). Neurology. 90(15_supplement).
8.
Sanjak, Mohammed, Nigel Rozario, Charity G. Patterson, et al.. (2017). Six-Minute Walk Test as a Measure of Walking Capacity in Ambulatory Individuals With Amyotrophic Lateral Sclerosis. Archives of Physical Medicine and Rehabilitation. 98(11). 2301–2307.
9.
Brooks, Benjamin Rix, Elena Bravver, Mohammed Sanjak, et al.. (2016). Adaptive Design Single Center Phosphodiesterase Type 4 (PDE4) Inhibitor - Ibudilast (MN-166-ALS-1201) Phase 1b/2a Clinical Trial Double-Blind (DB) with Open Label Extensions (OLE) [ NCT02238626 ] for Amyotrophic Lateral Sclerosis (ALS) Patients [1] Not Requiring Non-Invasive Ventilation (no-NIV) up to 5 Years (Early Cohort-EC) and [2] Requiring Non-Invasive Ventilation (NIV) up to 10 Years(Advanced NIV Cohort-ANC) from Disease Onset - Behavior of Creatinine as a Biomarker in Short Clinical Trials (P5.003). Neurology. 86(16_supplement).
10.
Hammond, Sara, et al.. (2015). Power Wheelchair Use in Persons With Amyotrophic Lateral Sclerosis: Changes Over Time. Assistive Technology. 27(4). 238–245.
11.
Brooks, Benjamin Rix, Michael J. M. Fischer, Mohammed Sanjak, et al.. (2014). Serum Creatinine, a Biomarker for Muscle Mass in Amyotrophic Lateral Sclerosis (ALS), Predicts Loss of Ambulation Measured by ALS Functional Rating Scale-Revised Walking Item Score (ALSFRS-Rw) (P4.085). Neurology. 82(10_supplement).
12.
Sanjak, Mohammed, Mark A. Hirsch, Elena Bravver, et al.. (2014). Vestibular Deficits Leading to Disequilibrium and Falls in Ambulatory Amyotrophic Lateral Sclerosis. Archives of Physical Medicine and Rehabilitation. 95(10). 1933–1939.
13.
Bravver, Elena, Mohammed Sanjak, & Benjamin Rix Brooks. (2013). Disease Severity and Disease Trajectory of Amyotrophic Lateral Sclerosis (ALS) Patients at Frist Clinic Visit Measured Prospectively with "ALS Dashboard" – A Six-Domain (Cognition, Affect, Bulbar, Respiratory, Arm, Leg) Staging System – Comparison of Two Cohorts (P07.088). Neurology. 80(7_supplement).
14.
Bravver, Elena, Charlotte L. Craig, Nicole Williams, et al.. (2013). The Joint Commission (TJC)/Disease-Specific Care (DSC) Certification Programs for Parkinson's Disease (PD)/Multiple Sclerosis (MS)/Amyotrophic Lateral Sclerosis (ALS) – A Structured Mechanism Developed for Guideline-Directed Performance Measure Implementation, Audit and Compliance Assessment Allowing Evolution from Process-Based to Patient-Outcome-Based Improvement in Patient Care at Carolinas Medical Center (P04.189). Neurology. 80(7_supplement).
15.
16.
Bravver, Elena, et al.. (2012). Timely Intervention of Non-Invasive Ventilation (NIV) To Treat Sleep-Ordered Breathing (SDB) Causing Respiratory Insufficiency (RI) in Amyotrophic Lateral Sclerosis (ALS) Patients Is Enhanced by Implementation of Home-Based Unattended Sleep Study (HBUSS): Results of the First Quarterly Audit at the Carolinas Neuromuscular/ALS-MDA Center (P01.104). Neurology. 78(Meeting Abstracts 1). P01.104–P01.104.
17.
Sanjak, Mohammed, Elena Bravver, William L. Bockenek, H. James Norton, & Benjamin Rix Brooks. (2010). Supported Treadmill Ambulation for Amyotrophic Lateral Sclerosis: A Pilot Study. Archives of Physical Medicine and Rehabilitation. 91(12). 1920–1929.
18.
Sanjak, Mohammed, et al.. (2010). Power Wheelchair Prescription, Utilization, Satisfaction, and Cost for Patients With Amyotrophic Lateral Sclerosis: Preliminary Data for Evidence-Based Guidelines. Archives of Physical Medicine and Rehabilitation. 91(2). 268–272.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Dagmar Kettemann Breakdown of academic impact, for papers by Nicola Cooke Breakdown of academic impact, for papers by Acary Bulle Oliveira Breakdown of academic impact, for papers by Paolo Volanti Breakdown of academic impact, for papers by Theresa Walsh Breakdown of academic impact, for papers by Bertram Walter Breakdown of academic impact, for papers by Elza Dias‐Tosta Breakdown of academic impact, for papers by Jonathan Marra Breakdown of academic impact, for papers by Stephen Wørlich Pedersen Breakdown of academic impact, for papers by Valentina Solara